Nelonemdaz is under clinical development by GNT Pharma and currently in Phase I for Acute Ischemic Stroke. According to GlobalData, Phase I drugs for Acute Ischemic Stroke have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nelonemdaz’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nelonemdaz overview
Nelonemdaz (Neu2000) is under development for the treatment of acute ischemic stroke, traumatic brain injury, traumatic spinal cord injury and burn injury, cerebral infarction. It is administered intravenously. It acts by targeting both NR2B-specific N-methyl-D-aspartate (NMDA) receptor and oxidative stress.
It was under development for acute myocardial infarction (AMI).
GNT Pharma overview
GNT Pharma (GNT Pharma Co) that manufactures botanical-based medicine, nutraceuticals, over-the-counter drugs, and veterinary medicine. The company is headquartered in Seongnam, Kyonggi-do, South Korea.
For a complete picture of Nelonemdaz’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
